ERBB2 and ovarian cancer: 225Ac in combination with trastuzumab, an anti-HER2/neu antibody, has also been tested in ovarian cancer mice models applying intraperitoneal injection and three levels of activities: 8.1, 12.2 and 16.7 kBq.